{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T21:31:34Z","timestamp":1789421494385,"version":"build-2803163510"},"reference-count":35,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2017,4,3]],"date-time":"2017-04-03T00:00:00Z","timestamp":1491177600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2017,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objective<\/jats:title><jats:p>The study mainly aimed at investigating possible correlations between peripheral blood counts, erythropoietin (<jats:styled-content style=\"fixed-case\">EPO<\/jats:styled-content>), <jats:italic><jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>2 V617F<\/jats:italic> mutation, and vascular complications prior to diagnosis of a population\u2010based cohort of newly diagnosed patients with myeloproliferative neoplasms (<jats:styled-content style=\"fixed-case\">MPN<\/jats:styled-content>).<\/jats:p><\/jats:sec><jats:sec><jats:title>Method<\/jats:title><jats:p>The study comprises 1105 patients with polycythemia vera (<jats:styled-content style=\"fixed-case\">PV<\/jats:styled-content>) and 1284 patients with essential thrombocythemia (<jats:styled-content style=\"fixed-case\">ET<\/jats:styled-content>) registered in the Swedish <jats:styled-content style=\"fixed-case\">MPN<\/jats:styled-content> Registry.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Vascular complications, prior to diagnosis, were registered in 37% of <jats:styled-content style=\"fixed-case\">PV<\/jats:styled-content> patients. In multivariate analysis, low hemoglobin was the only significant risk factor (<jats:italic>P<\/jats:italic>=.0120). Among <jats:styled-content style=\"fixed-case\">ET<\/jats:styled-content> patients, 35% had encountered a vascular complication. Risk factors for thromboembolic complications in <jats:styled-content style=\"fixed-case\">ET<\/jats:styled-content> were identified as age&gt;65\u00a0years, white cell count&gt;12\u00d710<jats:sup>9<\/jats:sup>\/L, and the presence of <jats:italic><jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>2 V617F<\/jats:italic> mutation (<jats:italic>P<\/jats:italic>=.0004, <jats:italic>P<\/jats:italic>=.0038, and <jats:italic>P<\/jats:italic>=.0016, respectively). A <jats:italic><jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>2 V617F<\/jats:italic> mutation was present in 71% of <jats:styled-content style=\"fixed-case\">ET<\/jats:styled-content> patients with vascular complications, compared to 60% in patients without. A majority of complications were thromboembolic, in both <jats:styled-content style=\"fixed-case\">PV<\/jats:styled-content> and <jats:styled-content style=\"fixed-case\">ET<\/jats:styled-content>.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>We conclude that vascular complications among newly diagnosed patients had affected more than one\u2010third of our study population. Risk factors for vascular complications prior to diagnosis were lower hemoglobin in <jats:styled-content style=\"fixed-case\">PV<\/jats:styled-content>, and the presence of <jats:italic><jats:styled-content style=\"fixed-case\">JAK<\/jats:styled-content>2 V617F<\/jats:italic> mutation, higher age, and leukocytosis in <jats:styled-content style=\"fixed-case\">ET<\/jats:styled-content>.<\/jats:p><\/jats:sec>","DOI":"10.1111\/ejh.12873","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T08:23:45Z","timestamp":1488443025000},"page":"577-583","source":"Crossref","is-referenced-by-count":26,"title":["Risk factors for vascular complications and treatment patterns at diagnosis of 2389 <scp>PV<\/scp> and <scp>ET<\/scp> patients: Real\u2010world data from the Swedish <scp>MPN<\/scp> Registry"],"prefix":"10.1111","volume":"98","author":[{"given":"Khadija","family":"Abdulkarim","sequence":"first","affiliation":[{"name":"Medical Department Kung\u00e4lv Hospital  Kung\u00e4lv Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Samuelsson","sequence":"additional","affiliation":[{"name":"Department of Education and Medical Science Karolinska Institute at Stockholm South Hospital  Stockholm Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Johansson","sequence":"additional","affiliation":[{"name":"Hematology section NU hospital group  Uddevalla Sweden"},{"name":"Hematology and Coagulation section Sahlgrenska University Hospital  Gothenburg Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1525-1331","authenticated-orcid":false,"given":"Bj\u00f6rn","family":"Andr\u00e9asson","sequence":"additional","affiliation":[{"name":"Hematology section NU hospital group  Uddevalla Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,4,3]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-209262"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-03-643544"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2008.01163.x"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2005.03.023"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)71142-9"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature03546"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051113"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428190701861652"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-02-292102"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa065202"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030270"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1311347"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1312542"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-12-379008"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-11-321737"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-04-495598"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2014.107714"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-03-559930"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-573089"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-143602"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.34.7542"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.57.6652"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2796.2004.01357.x"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-015-1983-5"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2008.004234"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.03.009"},{"key":"e_1_2_6_28_1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood.V124.21.632.632","article-title":"Risk of arterial and venous thrombosis in 11,155 patients with myeloproliferative neoplasms and 44,620 matched controls; a population based study","volume":"124","author":"Hultcrantz M","year":"2014","journal-title":"Blood"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2014.11.006"},{"key":"e_1_2_6_30_1","first-page":"191","article-title":"JAK2 V617F mutation burden and its clinical implications in 415 patients with myeloproliferative neoplasm","volume":"36","author":"Liu Y","year":"2015","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-04-153783"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.3569"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/794240"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23585"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2013.766732"},{"key":"e_1_2_6_36_1","unstructured":"LykkegaardAndersen C AndreassonB HasselbalchH et\u00a0al.Nordic Guidelines on the Diagnosis and Treatment of Patients with Myelopropliferative Neoplasms.2013; Available from:http:\/\/www.sfhem.se\/Files.aspx?f_id=91554. Accessed 15 Jan 2013"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fejh.12873","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.12873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,3]],"date-time":"2023-10-03T15:52:04Z","timestamp":1696348324000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.12873"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,3]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["10.1111\/ejh.12873"],"URL":"https:\/\/doi.org\/10.1111\/ejh.12873","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,3]]}}}